News News and Resources

Delpharm has announced a $220 million investment to modernise its pharmaceutical facility in Boucherville, Quebec. The funding includes $60 million from the provincial government, $60 million from the federal government, and $100 million in private capital. The company said the

Polpharma Biologics has confirmed that its mammalian cell culture facility in Duchnice has been approved by the European Medicines Agency (EMA) as a commercial manufacturing site. The approval adds Duchnice to the company’s network of authorised locations for drug substance

Indena and TCG GreenChem have announced a new strategic partnership aimed at advancing payload-linker development, a key component of Antibody-Drug Conjugates (ADCs). Indena, headquartered in Italy, specialises in the development and production of active pharmaceutical ingredients (APIs) and highly potent

Symbiosis Pharmaceutical Services, a global CMO specialising in the sterile manufacture of injectable drug products, has appointed Wendy Cook as a Qualified Person (QP). Cook brings more than two decades of pharmaceutical quality assurance experience, covering GLP, GCP and GMP

AmbioPharm, a global peptide contract development and manufacturing organisation (CDMO), is set to complete the expansion of its Shanghai Building 2 facility next month. The project will add nearly 75,000 square feet of commercial-scale manufacturing space. The expansion includes multiple

Made Scientific, a U.S.-based contract development and manufacturing organisation (CDMO) specialising in cell therapies, has announced the creation of its first Scientific Advisory Board (SAB). The board comprises Miguel Forte, M.D., Ph.D., Paul K. Wotton, Ph.D., Shishir Gadam, Ph.D., and

Sai Life Sciences Limited, a contract research, development, and manufacturing organisation (CRDMO), has completed Phase II of its new Production Block 11 (PB-11) at its flagship API manufacturing facility in Bidar, India. The expansion increases the block’s combined reactor capacity

George Medicines, a late-stage biopharma company, has partnered with Piramal Pharma Solutions (PPS), a global CDMO, to develop WIDAPLIK, a new drug for the treatment of hypertension in adults. The therapy has received FDA approval, marking it as the first

Altasciences, a contract research and contract development and manufacturing organisation (CRO/CDMO), has announced a strategic collaboration with Evidence Matters, a company specialising in clinical trial data science and document engineering. The partnership centres on Evidence Matters’ patent-pending Text Engineering technology